The Evaluation of Adverse Events in Clinical Trials (with a Particular Focus on the Use of Meta-Analysis)

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Unknown venue

• Publication date

  2014-04-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/9781118820186.CH9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Bayesian Hierarchical Modeling for Detecting Safety Signals in Clinical Trials

  2011cited by this paper
• Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies

  2011cited by this paper
• Data Mining and Statistically Guided Clinical Review of Adverse Event Data in Clinical Trials

  2009cited by this paper
• Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team

  2009cited by this paper
• The new Sentinel Network--improving the evidence of medical-product safety.

  2009cited by this paper
• Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events

  2007cited by this paper
• Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression.

  2007cited by this paper
• Applying the law of iterated logarithm to control type I error in cumulative meta-analysis of binary outcomes

  2007cited by this paper
• Inflamed joints and stiff arteries: is rheumatoid arthritis a cardiovascular risk factor?

  2006cited by this paper
• Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement

  2004cited by this paper
• What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.

  2004cited by this paper
• Accounting for Multiplicities in Assessing Drug Safety: A Three‐Level Hierarchical Mixture Model

  2004cited by this paper
• Use of the false discovery rate for evaluating clinical safety data

  2004cited by this paper
• Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomes

  2002cited by this paper
• Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice

  2002cited by this paper
• Statistical methods for assessing the influence of study characteristics on treatment effects in ‘meta‐epidemiological’ research

  2002cited by this paper
• On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions.

  2001cited by this paper
• Meta-Analysis in Medicine and Health Policy

  2000cited by this paper
• Exploring Heterogeneity in Randomized Trials Via Meta-Analysis

  1999cited by this paper
• Statistical Principles for Clinical Trials

  1998cited by this paper
• Explaining heterogeneity in meta-analysis: a comparison of methods.

  1997cited by this paper
• Investigating underlying risk as a source of heterogeneity in meta-analysis.

  1997cited by this paper
• Meta-Analysis and Response Surface Extrapolation: A Least Squares Approach

  1996cited by this paper
• Uncertainty of the time of first significance in random effects cumulative meta-analysis.

  1996cited by this paper
• A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction.

  1992cited by this paper
• Cumulative meta-analysis of therapeutic trials for myocardial infarction.

  1992cited by this paper

• No citing papers are available for this paper.